BIB

Fund Description
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index.
Fund Profile
Fund Name ProShares Ultra Nasdaq Biotechnology
Fund Exchange Ticker BIB
Fund Sponsor ProShares
Fund ISIN US74347R2141
Net Expense Ratio 0.95 %
Fund Inception Date 7 April 2010
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Leveraged / Inverse
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Nasdaq Biotech Index
Index Provider Nasdaq
Currency Hedged No
Inverse / Leveraged Leveraged (2x)
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 7 August 2020
Asset Under Management 228.97 Million (USD)
1 Month Total Return -6.62 %
Year To Date Return 15.82 %
1 Year Total Return 47.49 %
3 Year Annualized Total Return 8.66 %
NAV 71.5531
Share Outstanding 3,200,000
Top 10 Holdings (7 August 2020)
Constituent Name Constituent Ticker Constituent Type Weighting
EYEPOINT PHARMACEUTICALS INC EYPT EQUI
ACHILLION PHARMACEUTICALS INC COMMON STOCK USD ACHN EQUI
GUARDANT HEALTH INC GH EQUI
NOVOCURE LTD NVCR EQUI
IONIS PHARMACEUTICALS INC IONS EQUI
Net Other Assets / Cash CASH
EVOLUS INC EOLS EQUI
RESTORBIO INC TORC EQUI
PROQR THERAPEUTICS NV PRQR EQUI
SCHOLAR ROCK HOLDING CORP SRRK EQUI